Novavax Inc
NVAX6.690USD
+0.130+1.98%
交易中 （美东）报价延迟15分钟
1.08B总市值
2.26市盈率 TTM
关于 Novavax Inc 公司
Novavax, Inc. 是一家生物技术公司，致力于发现、开发和商业化用于预防严重传染病的疫苗。该公司提供差异化疫苗平台，该平台结合了重组蛋白方法、先进的纳米颗粒技术和其专利的 Matrix-M 佐剂来增强免疫反应。该公司有一个用于预防 COVID-19 的疫苗商业计划，其中包括 Nuvaxovid 原型 COVID-19 疫苗（NVX-CoV2373 或原型疫苗）和 Nuvaxovid 更新的 COVID-19 疫苗（NVX-CoV2601 或更新疫苗）（统称 COVID-19 疫苗）。该公司正在推进其他候选疫苗的开发，包括其 COVID19-流感联合 (CIC) 候选疫苗和其他候选疫苗。其 COVID-19 疫苗和其他候选疫苗结合了该公司专有的 Matrix-M 佐剂，以增强免疫反应并刺激更高水平的功能性抗体并诱导细胞免疫反应。
公司简介
公司代码NVAX
公司名称Novavax Inc
上市日期May 16, 1973
CEOMr. John C. Jacobs
员工数量952
证券类型Ordinary Share
年结日May 16
公司地址700 Quince Orchard Road
城市GAITHERSBURG
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编20878
电话12402682000
网址https://www.novavax.com/?locale=US
公司代码NVAX
上市日期May 16, 1973
CEOMr. John C. Jacobs
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
35.11K
+42.20%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Robert Walker, M.D.
Dr. Robert Walker, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
暂无数据
地区USD
名称
营收
占比
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
业务
地区
暂无数据
股东统计
更新时间: 6月4日 周三
更新时间: 6月4日 周三
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
股东类型
持股股东
占比
Investment Advisor
22.62%
Investment Advisor/Hedge Fund
18.46%
Hedge Fund
10.75%
Corporation
8.26%
Research Firm
4.80%
Pension Fund
0.81%
Individual Investor
0.52%
Bank and Trust
0.43%
Venture Capital
0.04%
Other
33.30%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
550
108.02M
66.69%
-12.99M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
2023Q1
1015
61.08M
70.93%
-3.17M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
15.64M
9.66%
-57.51K
-0.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.56M
7.14%
-518.90K
-4.30%
Mar 31, 2025
Shah Capital Management, Inc.
11.13M
6.87%
-17.00K
-0.15%
Mar 31, 2025
State Street Global Advisors (US)
7.04M
4.35%
-662.21K
-8.60%
Mar 31, 2025
Sanofi SA
6.88M
4.25%
--
--
Mar 31, 2025
SK Bioscience Co., Ltd.
6.50M
4.01%
--
--
May 10, 2024
Coatue Management, L.L.C.
3.84M
2.37%
+3.84M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
3.76M
2.32%
+106.31K
+2.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.26M
2.01%
-2.53M
-43.68%
Mar 31, 2025
Park West Asset Management LLC
2.53M
1.56%
+2.53M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Nanotechnology ETF
2.42%
iShares Genomics Immunology and Healthcare ETF
2.14%
Virtus LifeSci Biotech Products ETF
1.7%
ALPS Medical Breakthroughs ETF
0.69%
SPDR S&P Biotech ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
Invesco Nasdaq Biotechnology ETF
0.11%
First Trust Small Cap Growth AlphaDEX Fund
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
查看更多
ProShares Nanotechnology ETF
占比2.42%
iShares Genomics Immunology and Healthcare ETF
占比2.14%
Virtus LifeSci Biotech Products ETF
占比1.7%
ALPS Medical Breakthroughs ETF
占比0.69%
SPDR S&P Biotech ETF
占比0.41%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.23%
Invesco Nasdaq Biotechnology ETF
占比0.11%
First Trust Small Cap Growth AlphaDEX Fund
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.11%
iShares Biotechnology ETF
占比0.1%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
